A new mouse model of autoimmune ocular myasthenia gravis

Investigative Ophthalmology and Visual Science

Volumn 48, Issue 11, 2007, Pages 5101-5111

  Yang, Huan ^a,c   Wu, Bo ^b,d   Tüzün, Erdem ^a,e   Saini, Shamsher S ^a   Li, Jing ^a   Allman, Windy ^a   Higgs, Stephen ^a   Xiao, Tian Lin ^a   Christadoss, Premkumar ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d Tarrant County College   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; HLA DQ8 ANTIGEN; HLA DR3 ANTIGEN; IMMUNOGLOBULIN G; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEIN SUBUNIT; RECOMBINANT RECEPTOR; HLA DQ ANTIGEN; NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; C57BL 10 MOUSE; C57BL 6 MOUSE; CD4+ T LYMPHOCYTE; DISEASE MODEL; DISEASE PREDISPOSITION; DISEASE SEVERITY; ESCHERICHIA COLI; EXPRESSION VECTOR; EYE MALFORMATION; EYELID; IMMUNITY; IMMUNIZATION; IMMUNOPATHOGENESIS; INCIDENCE; LIMB; MOUSE; MYASTHENIA GRAVIS; NEUROMUSCULAR SYNAPSE; NONHUMAN; OCULAR MYASTHENIA GRAVIS; PLASMID; PRIORITY JOURNAL; TRANSGENIC MOUSE; ANIMAL; C57BL MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EYE MOVEMENT DISORDER; FEMALE; FLUORESCENCE MICROSCOPY; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PATHOLOGY; RADIOIMMUNOASSAY; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; COMPLEMENT C3; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENE EXPRESSION; HLA-DQ ANTIGENS; HLA-DR3 ANTIGEN; LYMPHOCYTE ACTIVATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICROSCOPY, FLUORESCENCE; MYASTHENIA GRAVIS, AUTOIMMUNE, EXPERIMENTAL; OCULAR MOTILITY DISORDERS; PLASMIDS; RADIOIMMUNOASSAY; RECEPTORS, NICOTINIC;

EID: 38449118595     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: 10.1167/iovs.07-0271     Document Type: Article

References (23)

1. Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann NY Acad Sci. 1987;505:472-499.
2. Gunji K, Skolnick C, Bednarczuk T, et al. Eye muscle antibodies in patients with ocular myasthenia gravis: possible mechanism for eye muscle inflammation in acetylcholine-receptor antibody-negative patients. Clin Immunol Immunopathol. 1998;87:276-281.
3. Christadoss P, Poussin M, Deng C. Animal models of myasthenia gravis. Clin Immunol. 2000;94:75-87.
4. Christadoss P, Lennon VA, Krco CJ, et al. Genetic control of autoimmunity to acetylcholine receptors: role of Ia molecules. Ann NY Acad Sci. 1981;377:258-277.
5. Christadoss P, Lindstrom J, Munro S, Talal N. Muscle acetylcholine receptor loss in murine experimental autoimmune myasthenia gravis: correlated with cellular, humoral and clinical responses. J Neuroimmunol. 1985;8:29-41.
6. Yang H, Goluszko E, David C, et al. Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. J Clin Invest. 2002;109:1111-1120.
7. Naeim F, Keesey JC, Herrmann C Jr, et al. Association of HLA-B8, DRw3, and anti-acetylcholine receptor antibodies in myasthenia gravis. Tissue Antigens. 1978;12:381-386.
8. Beeson D, Morris A, Vincent A, Newsom-Davis J. The human muscle nicotinic acetylcholine receptor alpha-subunit exists as two isoforms: a novel exon. EMBO J. 1990;9:2101-2106.
9. Talib S, Okarma TB, Lebkowski JS. Differential expression of human nicotinic acetylcholine receptor alpha subunit variants in muscle and non-muscle tissues. Nucleic Acids Res. 1993;21:233-237.
10. Abraham RS, Kudva YC, Wilson SB, et al. Co-expression of HLA DR3 and DQ8 results in the development of spontaneous insulitis and loss of tolerance to GAD65 in transgenic mice. Diabetes. 2000;49:548-554.
11. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
12. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
13. Wu B, Goluszko E, Christadoss P. Experimental autoimmune myasthenia gravis in the mouse. In: Coligan M, Shevach, Strober, eds. Current Protocols of Immunology. Vol. 3:15. New York: John Wiley & Sons; 1997:8.1-8.16.
14. Tuzun E, Scott BG, Goluszko E, et al. Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis. J Immunol. 2003;171:3847-3854.
15. Henikoff S, Henikoff JG. Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci USA. 1992;89:10915-10919.
16. Kaminski HJ. Acetylcholine receptor epitopes in ocular myasthenia. Ann NY Acad Sci. 1998;841:309-319.
17. Saini SS, Tuzun E, Christadoss P. The cDNA of mouse skeletal muscle transcribe for both isoforms 1 and 2 of acetylcholine receptor alpha subunit. J Neuroimmunol. 2005;169:177-179.
18. Porter JD, Khanna S, Kaminski HJ, et al. Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc Natl Acad Sci USA. 2001;98:12062-12067.
19. Miwa T, Song WC. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol. 2001;1:445-459.
20. Lennon VA, Lambert EH, Leiby KR, et al. Recombinant human acetylcholine receptor alpha-subunit induces chronic experimental autoimmune myasthenia gravis. J Immunol. 1991;146:2245-2248.
21. Carlsson B, Wallin J, Pirskanen R, et al. Different HLA DR-DQ associations in subgroups of idiopathic myasthenia gravis. Immunogenetics. 1990;31:285-290.
22. Buchwald B, Ahangari R, Toyka KV. Differential blocking effects of the monoclonal anti-GQ1b IgM antibody and alpha-latrotoxin in the absence of complement at the mouse neuromuscular junction. Neurosci Lett. 2002;334:25-28.
23. Goodyear CS, O'Hanlon GM, Plomp JJ, et al. Monoclonal antibodies raísed against Guillain-Barre syndrome-associated Campylobacter jejuni lipopolysaccharídes react with neuronal ganglíosides and paralyze muscle-nerve preparations. J Clin Invest. 1999; 104:697-708.